Life Sciences Gets a COVID Booster Shot

Three veterans of the life sciences private equity and M&A market share intel about dramatic changes in the industry. Sean Cunningham from private equity firm GTCR and Adam Lohr and Jamie Hendershot of RSM discuss what’s driving the surging IPO market for biotech companies, how clinical trials have continued apace during COVID, considerations for investing in tool-making companies versus drug developers, and the need for private equity partners to bring more to the table than just money.

Download Report

Register now to download this report and access all content.

It's FREE!

Email*
Username*
Name*
First Last
Title*
Firm Name*
Firm Type*
Zip Code*
Password*
Enter Password Confirm Password
Hidden
Choose your newsletters
CHOOSE YOUR NEWSLETTERS:
- Private Equity
- Real Estate
Choose your newsletters*
I agree to the Privcap terms of use and privacy policy
- Yes
Already a subscriber? Sign In
Name
This field is for validation purposes and should be left unchanged.

- Media Partners

Privcap Email Updates

Subscribe to receive email notifications whenever new talks are published.

Life Sciences Gets a COVID Booster Shot

Register now to download this report and access all content.

It's FREE!

Already a subscriber? Sign In

Privcap Email Updates